European Biotechs Face Harsh Reality
This article was originally published in Start Up
With IPOs now beyond the reach of all but a chosen few biotech firms, venture capitalists are driving hard bargains--when they're not seeking M&A opportunities. The infrastructure to take companies public now exists in Europe, but institutional investors have little interest in small biotech companies whose products are far from commercialization. If they're going to take risk, they want the promise of Internet-type returns. European VCs under pressure to boost the market appeal of their current portfolio firms are busy assessing the masses of existing companies, seeking M&A opportunities to build up their favorites. Some are pursuing e-health deals. VCs now realize they'll have to hold biotech companies longer and put in more money to help them grow. But the fact that so many firms now need cash works in some VCs' favor: biotech is a buyer's game. Like their US counterparts, European VCs are seeking new, improved biotech business models. They want reduced risk, near-term revenue potential and technological depth--for starters. There are bright spots amid the gloom: some small pre-VC funds are emerging to help start ups set up, and the governments of several European countries are working to encourage biotech.
You may also be interested in...
Earlybird hopes to capitalize on the convergence of information technologies with health care. It sees these two sectors not as separate strands with fundamentally different investment strategies, but rather as areas whose increasing overlap presents a new pool of companies needing support with experience in both businesses, and, the contend, bi-continental reach.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.